A global quantitative survey of hemostatic assessment in postpartum hemorrhage and experience with associated bleeding disorders

Andra H James, David L Cooper, Michael J Paidas, Andra H James, David L Cooper, Michael J Paidas

Abstract

Purpose: Coagulopathy may be a serious complicating or contributing factor to postpartum hemorrhage (PPH), and should be promptly recognized to ensure proper bleeding management. This study aims to evaluate the approaches of obstetrician-gynecologists worldwide towards assessing massive PPH caused by underlying bleeding disorders.

Methods: A quantitative survey was completed by 302 obstetrician-gynecologists from 6 countries (the UK, France, Germany, Italy, Spain, and Japan). The survey included questions on the use of hematologic laboratory studies, interpretation of results, laboratory's role in coagulation assessments, and experience with bleeding disorders.

Results: Overall, the most common definitions of "massive" PPH were >2,000 mL (39%) and >1,500 mL (34%) blood loss. The most common criteria for rechecking a "stat" complete blood count and for performing coagulation studies were a drop in blood pressure (73%) and ongoing visible bleeding (78%), respectively. Laboratory coagulation (prothrombin time/activated partial thromboplastin time [PT/aPTT]) and factor VIII/IX assays were performed on-site more often than were mixing studies (laboratory coagulation studies, 93%; factor VIII/IX assays, 63%; mixing studies, 22%). Most commonly consulted sources of additional information were colleagues within one's own specialty (68%) and other specialists (67%). Most respondents had consulted with a hematologist (78%; least, Germany [56%]; greatest, UK [98%]). The most common reason for not consulting was hematologist unavailability (44%). The most commonly reported thresholds for concern with PT and aPTT were 13 to 20 seconds (36%) and 30 to 45 seconds (50%), respectively. Most respondents reported having discovered an underlying bleeding disorder (58%; least, Japan [35%]; greatest, Spain [74%]).

Conclusion: Global survey results highlight similarities and differences between countries in how PPH is assessed and varying levels of obstetrician-gynecologist experience with identification of underlying bleeding disorders and engagement of hematology consultants. Opportunities to improve patient management of PPH associated with bleeding disorders include greater familiarity with interpreting PT/aPTT test results and identification of and consistent consultation with hematologists with relevant expertise.

Keywords: acquired hemophilia; bleeding disorders; coagulation studies; hematologist; postpartum hemorrhage.

Conflict of interest statement

Disclosure David L Cooper is an employee of Novo Nordisk Inc. Andra H James and Michael J Paidas report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Strategies used for the management of postpartum hemorrhage: uterotonics (A); surgery (B); and blood/factor products (C).
Figure 2
Figure 2
Frequency of hematology consultations (A) and reasons for not consulting hematology (B).
Figure 3
Figure 3
PT (A) and aPTT (B) thresholds for concern. Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time.

References

    1. Bonnet MP, Deneux-Tharaux C, Bouvier-Colle MH. Critical care and transfusion management in maternal deaths from postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):183–188.
    1. Borna S, Hantoushzadeh S. Acquired hemophilia as a cause of primary postpartum hemorrhage. Arch Iran Med. 2007;10(1):107–110.
    1. Brace V, Kernaghan D, Penney G. Learning from adverse clinical outcomes: major obstetric haemorrhage in Scotland, 2003–2005. Br J Obstet Gynaecol. 2007;114(11):1388–1396.
    1. James AH, McLintock C, Lockhart E. Postpartum hemorrhage: When uterotonics and sutures fail. Am J Hematol. 2012;87(S1):S16–S22.
    1. Sheikh L, Najmi N, Khalid U, Saleem T. Evaluation of compliance and outcomes of a management protocol for massive postpartum hemorrhage at a tertiary care hospital in Pakistan. BMC Pregnancy Childbirth. 2011;11:28.
    1. Wise A, Clark V. Challenges of major obstetric haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2010;24(3):353–365.
    1. Montufar-Rueda C, Rodriguez L, Jarquin JD, et al. Severe postpartum hemorrhage from uterine atony: a multicentric study. J Pregnancy. 2013;2013:525914.
    1. Silver RM, Major H. Maternal coagulation disorders and postpartum hemorrhage. Clin Obstet Gynecol. 2010;53(1):252–264.
    1. Collins PW, Hirsch S, Baglin TP, et al. UK Haemophilia Centre Doctors’ Organisation Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Oganisation. Blood. 2007;109(5):1870–1877.
    1. Kessler CM, Ludlam CA. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Semin Hematol. 1993;30(2 Suppl 1):22–27.
    1. Lak M, Sharifian RA, Karimi K, Mansouritorghabeh H. Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa. Clin Appl Thromb Hemost. 2010;16(3):294–300.
    1. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81(6):1513–1520.
    1. Paidas MJ, Hossain N. Unexpected postpartum hemorrhage due to an acquired factor VIII inhibitor. Am J Perinatol. 2014;31(8):645–654.
    1. Tengborn L, Baudo F, Huth-Kühne A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. Br J Obstet Gynaecol. 2012;119(12):1529–1537.
    1. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295–307.
    1. Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis. 2016;27(7):753–760.
    1. Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry. Haemophilia. 2016;22(1):e18–e24.
    1. James AH, Cooper DL, Paidas MJ. Hemostatic assessment, treatment strategies, and hematology consultation in massive postpartum hemorrhage: results of a quantitative survey of obstetrician-gynecologists. Int J Womens Health. 2015;7:873–881.
    1. Reding MT, Cooper DL. Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey. J Multidiscip Healthc. 2012;5:277–287.
    1. Rehman HU. Elevated APTT? How best to follow up. J Fam Pract. 2013;62(6):E1–E3.
    1. Tripodi A, Lippi G, Plebani M. How to report results of prothrombin and activated partial thromboplastin times. Clin Chem Lab Med. 2016;54(2):215–222.
    1. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864–873.
    1. Lenox C, Marr L. Scottish Confidential Audit of Severe Maternal Morbidity, 7th Annual Report. Edinburgh, Scotland: Healthcare Improvement Scotland; 2011. pp. 1–42.
    1. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg. 2010;110(5):1368–1373.
    1. James AH, Paglia MJ, Gernsheimer T, Grotegut C, Thames B. Blood component therapy in postpartum hemorrhage. Transfusion. 2009;49(11):2430–2433.
    1. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165–1169.
    1. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008;14(Suppl 3):49–55.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere